NEW YORK (TheStreet) -- CHANGE IN RATINGS
rated new Buy at Citigroup. Acquisition of NT assets makes sense, especially with a low price tag. $17.50 price target.
upgraded at BofA Merrill. Rating raised to Neutral from Underperform. Price target raised to $32 from $22. 2009 EPS estimates raised to $2.13 from $1.92.
upgraded at Goldman. $95 price target. Company has a new product cycle and the sales ramp should drive higher margins.
upgraded at Fox-Pitt from In-Line to Outperform. Estimates also raised, to reflect higher expected market share. $29 price target.
upgraded at Barclays to Equal Weight from Underweight. Shares now seen reaching $49, up from $35. 2009 and 2010 EPS estimates increased to $2.63 from $2.53 and to $2.45 from $2.43, respectively.
downgraded at Goldman from Buy to Neutral. $45 price target. See limited upside to current earnings expectations, as core growth is slowing.
downgraded at BofA Merrill. Rating lowered to Underperform from Neutral. Maintains $18 price target. Lowers 2009 EPS estimates to $1.60 from $1.65.
downgraded at Goldman from Buy to Neutral. Valuation call, based on a $24 price target. See better upside potential in TXN.
upgraded at Citigroup from Sell to Buy. $61 price target. See significant earnings leverage, as same-store sales improve.
upgraded at Goldman from Neutral to Buy. Market underestimates the ability to grow margins over the next several quarters. $29 price target.
numbers boosted at UBS. Shares of WAT now seen reaching $63. Estimates also raised, to reflect stable end markets and lower expenses. Neutral rating.
numbers lowered at Goldman. Shares of X now seen reaching $49. Estimates also cut, to reflect weakness in the flat rolled division. Buy rating.
STOCK COMMENTS / EPS CHANGES
estimates, target increased at Citigroup. Estimates were raised through 2011. Company raised guidance for higher organic sales. Buy rating and new $155 price target.
estimates, target boosted at Goldman. Shares of AGCO now seen reaching $35. Estimates also increased, to reflect better cost controls and demand in South America. Neutral rating.
estimate higher as Barclays. 2010 EPS estimates up by a penny to $5.20. Reiterate Overweight rating and $100 price target.
estimates boosted at UBS through 2010. Cost-cutting efforts are driving earnings higher. Sell rating and $30 price target.
estimates, target increased at UBS. Shares of BEAV now seen reaching $20. Estimates were also raised, to reflect higher realized margins. Neutral rating.
numbers raised at Citigroup. Shares of BEN now seen reaching $126. Estimates also increased, to reflect higher expected asset inflows. Buy rating.
added to Conviction Buy list at Goldman Sachs. Estimates also raised, as the company has several catalysts that could boost margins. New $26 price target.
estimates raised at Goldman through 2013. Company is seeing lower research and operating expenses. Buy rating and $67 price target.
estimates mixed at Credit Suisse. CNC 2009 EPS estimate increased by 2 cents to $1.95, 2010 cut by 2 cents to $2.10. Maintain Neutral rating and $22 price target.
numbers increased at Goldman through 2011. Company boosted its production guidance and is realizing higher natural gas prices. Neutral rating and new $47 price target.
price target, estimates increased at Credit Suisse. Price target raised to $68 from $65 after strong 3Q results. 2009 and 2010 EPS estimates boosted to $2.50 from $2.32 and to $3.22 from $3.00, respectively. Maintain Neutral rating.
numbers raised at Morgan Stanley. Shares of CPLA now seen reaching $70. Estimates also boosted, to reflect higher enrollment growth and margin expectations. Equal-weight rating.
price target, estimates higher at Barclays. CR price target raised to $32 from $30. 2009 and 2010 EPS estimates lifted to $2.00 from $1.85 and to $2.15 from $1.90, respectively. Reiterate Equal Weight rating.
numbers increased at UBS. Shares of CTV now seen reaching $30. Estimates also boosted, to reflect higher realized margins. Neutral rating.
price target, estimates boosted at Credit Suisse. CVG price target lifted to $15 from $13. 2009 EPS estimate raised to $1.10 from $1.00, 2010 introduced at $1.25. Maintain Outperform rating.
estimates boosted at UBS through 2010. Company is seeing lower expenses and tax rate, and 2010 should bring a better film slate. Neutral rating and $34 price target.
price target, estimates raised at Barclays. EP price target increased by a dollar to $13. Maintain Overweight rating. 2009 and 2010 EPS estimates increased to $1.08 and $1.24, respectively.
estimates, target boosted at Goldman. EXC estimates were raised through 2012. Company is cutting costs. Buy rating and new $64 price target.
estimates, target reduced at Morgan Stanley. FPL estimates were cut through 2011. Rate case has been delayed, and the company lost some tax credits. Underweight rating and new $50.50 price target.
price target, estimates increased at Barclays. GAS price target raised by a dollar to $38. 2009 and 2010 EPS estimates inflated to $2.61 and $2.97, respectively. Reiterate Underweight rating.
estimates, target boosted at UBS. HRS estimates were raised through 2011. Company seeing strong orders. Buy rating and new $47 price target.
Heidrick & Struggle
price target, estimates boosted at Credit Suisse. HSII price target lifted to $26 from $20. 2009 and 2010 EPS estimates raised to -$0.25 and $0.50, respectively. Maintain Neutral rating.
estimates reduced at Goldman. HXL estimates were lowered through 2011. Company is seeing falling operating margins. Neutral rating and $13 price target.
numbers boosted at Bernstein. Shares of IACI now seen reaching $23. Estimates were also raised, to reflect solid margin trends. Market Perform rating.
estimates lowered at UBS through 2010. Company is seeing order delays and was hurt by manufacturing issues. Buy rating and $45 price target.
numbers increased at UBS through 2010. Company is seeing higher flu sales and acquisitions are paying off. Buy rating and new $47 price target.
numbers increased at Goldman. Shares of JCI now seen reaching $22. Estimates also boosted, to reflect a higher margin outlook. Sell rating.
numbers raised at UBS. Shares of LIFE now seen reaching $59. Estimates were also increased, to reflect higher flu sales and research demand. Buy rating.
estimates boosted at Goldman through 2011. Company is seeing better growth, though relatively less than its peers. Should also benefit from a lower tax rate. Sell rating and $66 price target.
target, estimates boosted at Barclays. Barclays raised LLL price target to $95 from $90 on strong 3Q, valuation. 2009 EPS estimate raised by a quarter to $7.50, 2010 lifted to $7.95 from $7.80. Maintain Overweight rating.
numbers boosted at Citigroup. Shares of MCK now seen reaching $77. Estimates also raised, to reflect a stronger flu season and cost cutting. Buy rating.
estimates raised at Goldman through 2010. Better sales are driving higher margins and the company is also realizing a lower tax rate. Buy rating and $27 price target.
estimates boosted at Morgan Stanley through 2011. Company is cutting costs and management was positive about future price and volume trends. Equal-weight rating.
estimates raised at Barclays. NSC 2009 and 2010 EPS estimate up to $2.77 and $3.70, respectively. Maintain Equal Weight rating and $51 price target.
estimates lowered at Goldman through 2010. Company is seeing higher operating costs. Neutral rating and $38 price target.
estimates boosted at Morgan Stanley through 2011. Strong relationships with NOK and Samsung are helping to drive growth. Underweight rating.
RF Micro Devices
price target, estimates boosted at Barclays. RFMD shares now seen reaching $5.50. 2010 and 2011 EPS estimates raised to $0.40 and $0.45, respectively. Reiterate Equal Weight price target.
numbers reduced at Goldman. SCHN estimates were cut through 2012. Margins are down in the metal recycling business, because of higher competition. Sell rating and new $40 price target.
added to Top Picks list at Citigroup. $28 price target. Stock appears oversold, relative to its risks to commercial real estate and construction. Buy rating.
estimates reduced at Goldman through 2010. Company facing higher restructuring costs and dilution from the recent convertible offering. Buy rating and $25 price target.
price target raised at Barclays to $84 from $75 on belief that comps will turn positive in 4Q. 2010 EPS estimate set at $3.50. Maintain Equal Weight rating.
target raised at Citigroup. Shares of V now seen reaching $80. Company is positioned well to benefit from a recovery in U.S. spending. Hold rating.
price target, estimates changed at Barclays. Price target up to $22 from $20. 2009 EPS estimate raised to $0.96, 2010 cut to $1.42. Maintain Overweight rating.
This article was written by a staff member of TheStreet.com.